Time to progression of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response measures · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events and complications · people with liver metastases
1 finding from 1 review
Death during study period · people with liver metastases
It is very uncertain whether transarterial chemoembolisation changes mortality at 44 months from trial entry Number of participants compared with no intervention (very low certainty).
1 finding from 1 review
Survival time Median (range) survival time after trial entry Survival time Median (range) survival time from diagnosis · people with liver metastases
1 finding from 1 review
Failure to clear liver metastases or recurrence of liver metastases · people with liver metastases
1 finding from 1 review
Time to progression of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response measures · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Survival time Median (range) survival time after trial entry Survival time Median (range) survival time from diagnosis · people with liver metastases
1 finding from 1 review
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events and complications · people with liver metastases
1 finding from 1 review
Failure to clear liver metastases or recurrence of liver metastases · people with liver metastases
1 finding from 1 review
Time to progression of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response measures · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events and complications · people with liver metastases
1 finding from 1 review
Death during study period · people with liver metastases
It is very uncertain whether transarterial embolisation changes mortality at 44 months from trial entry Number of participants compared with no intervention (very low certainty).
1 finding from 1 review
Survival time Median (range) survival time after trial entry Survival time Median (range) survival time from diagnosis · people with liver metastases
1 finding from 1 review
All‐cause mortality · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes all‐cause mortality compared with no intervention (very low certainty).
1 finding from 1 review